Table 2.
Cost Analysis: Prematch and Postmatch Cohorts
| Cost analysis |
Prematch cohorts |
Postmatch cohorts |
||||
|---|---|---|---|---|---|---|
| IVIG cohort (N = 986) | SCIG cohort (N = 653) | P value | IVIG cohort (N = 553) | SCIG cohort (N = 553) | P value | |
| Total all-cause costs | ||||||
| Mean (SD), $ | 103,177 (± 113,723) | 71,949 (± 59,209) | <.001a | 80,089 (± 81,702) | 73,108 (± 57,559) | .101 |
| Median, $ | 66,568 | 57,296 | <.001a | 58,095 | 59,726 | .711 |
| PIDD-related total costs | ||||||
| Mean (SD), $ | 45,225 (± 44,863) | 48,517 (± 38,255) | .042 | 45,713 (± 40,844) | 49,630 (± 38,714) | .102 |
| Median,a $ | 36,277 | 41,339 | .001 | 38,064 | 43,266 | .002 |
| PIDD-related pharmacy costs | ||||||
| Mean (SD), $ | 24,259 (± 24,575) | 25,584 (± 23,911) | .280 | 23,331 (± 20,206) | 26,565 (± 24,818) | .030 |
| Median,a $ | 19,037 | 22,073 | <.001 | 19,195 | 23,097 | .002 |
| Immunoglobulin drug costs | ||||||
| Mean (SD), $ | 23,271 (± 24,033) | 24,626 (± 23,870) | .313 | 22,475 (± 19,953) | 25,475 (± 24,775) | .035 |
| Median,a $ | 18,082 | 21,242 | <.001 | 18,449 | 21,773 | <.001 |
| Administration costs | ||||||
| Mean (SD), $ | 988 (± 1742) | 1094 (± 1627) | .207 | 856 (± 1026) | 1089 (± 1804) | .267 |
| Median, $ | 600 | 550 | .593 | 581 | 300 | <.001a |
a
Significant difference.
IVIG indicates intravenous immunoglobulin; PIDD, primary immune-deficiency disorder; SCIG, subcutaneous immunoglobulin; SD, standard deviation.